<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201212105623N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-12-26</date_registration>
      <primary_sponsor>Kashan University Of Medical Science</primary_sponsor>
      <public_title>Effects of supplementation in treatment of pregnancy complications</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of effectiveness of multivitamin, multivitamin-mineral supplements, synbiotic and normal Gaz on pregnancy outcomes in pregnant women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2011-08-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>298</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/6033</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: At study baseline, after balance randomization, subjects will be divided into groups to take either supplements or control. 
 Intervention group 1: Multivitamin-mineral supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, 125 mg calcium, 18 mg iron, 100 mg magnesium, daily, for 20 weeks.
Control group 1: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks.

Intervention group 2: Synbiotic Gaz containing Lactobacillus sporogenes 107 CFU/g, 0.04 g inulin, 0.38 g isomalt, 0.36 g sorbitol and 0.05 g stevia per 1 g, 9 g, twice a day for 9 weeks.
Control group 2: Normal Gaz, 9 g, twice a day for 9 weeks.
Intervention group 3: Multivitamin-mineral supplements containing 4000 IU vitamin A, 11 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.8 mg vitamin B2, 18 mg niacin, 2.8 mg vitamin B6, 800 µg folic acid, 4 µg vitamin B12, 100 mg vitamin C, 250 mg calcium, 27 mg iron, 25 mg zinc, daily, for 20 weeks.
Control group 3: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks.
Randomization will be done by the use of computer-generated random numbers, Blinding description: Participants, investigators or the assessors of the outcomes are unaware of the study groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Multivitamin-mineral supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, 125 mg calcium, 18 mg iron, 100 mg magnesium, daily, for 20 weeks. Intervention 2: Control group 1: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks. Intervention 3: Intervention group 2: Synbiotic Gaz containing Lactobacillus sporogenes 107 CFU/g, 0.04 g inulin, 0.38 g isomalt, 0.36 g sorbitol and 0.05 g stevia per 1 g, 9 g, twice a day for 9 weeks. Intervention 4: Control group 2: Normal Gaz, 9 g, twice a day for 9 weeks. Intervention 5: Intervention group 3: Multivitamin-mineral supplements containing 4000 IU vitamin A, 11 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.8 mg vitamin B2, 18 mg niacin, 2.8 mg vitamin B6, 800 µg folic acid, 4 µg vitamin B12, 100 mg vitamin C, 250 mg calcium, 27 mg iron, 25 mg zinc, daily, for 20 weeks. Intervention 6: Control group 3: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Undecided - It is not yet known if there will be a plan to make this available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zatollah Asemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghotbe Ravandi Boulevard, Kashan</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1771844351</zip>
        <telephone>+98 31 5546 3378</telephone>
        <email>asemi_r@yahoo.com</email>
        <affiliation>Kashan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zatollah Asemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghotbe Ravandi Boulevard, Kashan</address>
        <city>Kashan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8719844189</zip>
        <telephone>+98 36 1446 3378</telephone>
        <email>asemi_za@yahoo.com</email>
        <affiliation>Kashan University Of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women primigravida
Aged 18-35 year old who were carrying singleton pregnancy at their second and third trimester</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Multiparous women
Patients with hypertension
Gestational diabetes mellitus (GDM)
Complete bed rest (CBR)
Intra uterine fetal death (IUFD)
Placenta abruption
Preterm delivery
Intrauterine growth restriction (IUGR)
History of rheumatoid arthritis, thyroid, parathyroid or adrenal diseases
Hepatic or renal failure
Hospitalization
Signs of malabsorption and maldigestion
Metabolic bone disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>094</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sequelae of complication of pregnancy, childbirth and the puerperium</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Multivitamin-mineral supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, 125 mg calcium, 18 mg iron, 100 mg magnesium, daily, for 20 weeks.</i_keyword>
      <i_keyword>Control group 1: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks.</i_keyword>
      <i_keyword>Intervention group 2: Synbiotic Gaz containing Lactobacillus sporogenes 107 CFU/g, 0.04 g inulin, 0.38 g isomalt, 0.36 g sorbitol and 0.05 g stevia per 1 g, 9 g, twice a day for 9 weeks.</i_keyword>
      <i_keyword>Control group 2: Normal Gaz, 9 g, twice a day for 9 weeks.</i_keyword>
      <i_keyword>Intervention group 3: Multivitamin-mineral supplements containing 4000 IU vitamin A, 11 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.8 mg vitamin B2, 18 mg niacin, 2.8 mg vitamin B6, 800 µg folic acid, 4 µg vitamin B12, 100 mg vitamin C, 250 mg calcium, 27 mg iron, 25 mg zinc, daily, for 20 weeks.</i_keyword>
      <i_keyword>Control group 3: Multivitamin supplements containing 5000 IU vitamin A, 15 IU vitamin E, 400 IU vitamin D3, 1.5 mg vitamin B1, 1.7 mg vitamin B2, 20 mg niacin, 2 mg vitamin B6, 400 µg folic acid, 6 µg vitamin B12, 60 mg vitamin C, daily, for 20 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</prim_outcome>
      <prim_outcome>Iron. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</prim_outcome>
      <prim_outcome>Total glutathione. Timepoint: Baseline and end-of-trial. Method of measurement: Spectrophotometry.</prim_outcome>
      <prim_outcome>Insulin. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit.</prim_outcome>
      <prim_outcome>Newborns' weight. Timepoint: Delivery time. Method of measurement: Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Calcium. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Vitamin D. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit.</sec_outcome>
      <sec_outcome>Magnesium. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Zinc. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Total antioxidant. Timepoint: Baseline and end-of-trial. Method of measurement: Spectrophotometry.</sec_outcome>
      <sec_outcome>Newborn's head circumference. Timepoint: The first 24 h after birth. Method of measurement: Tape.</sec_outcome>
      <sec_outcome>Newborn's length. Timepoint: The first 24 h after birth. Method of measurement: Tape.</sec_outcome>
      <sec_outcome>Apgar score. Timepoint: Delivery time. Method of measurement: Clinical observation.</sec_outcome>
      <sec_outcome>Triglycerides. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Cholesterol. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Insulin resistance. Timepoint: Baseline and end-of-trial. Method of measurement: Using HOMA formula.</sec_outcome>
      <sec_outcome>VLDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>LDL. Timepoint: Baseline and end-of-trial. Method of measurement: Enzymatic kit.</sec_outcome>
      <sec_outcome>Hs-CRP. Timepoint: Baseline and end-of-trial. Method of measurement: Elisa kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kashan University Of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-08-09</approval_date>
        <contact_name>Kashan University of Medical Sciences</contact_name>
        <contact_address>Ghotbe Ravandi Boulevard, Kashan Kashan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
